北京若生智能科技有限公司
Drug Database
ME

mesalazine (Rowasa / Pentasa enema / Pentasa foam enema)

✓ Approved

Nisshin Pharma · PTGS1 · 小分子

什么是 mesalazine？

mesalazine 是一种小分子，由Nisshin Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Rectal。

药物档案

商品名Rowasa, Pentasa enema, Pentasa foam enema
公司Nisshin Pharma
药物类别小分子
分子靶点PTGS1, PTGS2
给药途径Rectal
状态Approved
来源： ClinicalTrials.gov, Nisshin Pharma

作用机制

分子靶点

mesalazine 作用于 2 个分子靶点：

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

mesalazine 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved

相关研究文献

PubMedPsychology, health & medicine2026-10-26

Effect of breathing exercise on enema-related anxiety, fear and pain in children: a randomized controlled trial.

Padir Zeynep Z, Turk Dudukcu Figen F

To explore the effects of breathing exercises on enema-related anxiety, fear, and pain in children. A randomized controlled trial (RCT) design was adopted. Children aged 6-12 (n = 106) were randomly assigned to an intervention group (n = 53) and a control group (n = 53). The intervention group received breathing exercises. Comparisons of pain, fear, and anxiety scores both between and within the two groups were conducted using independent samples t-tests. Cohen's d formula was used to calculate the effect size of the difference between the two group averages. The intervention group received breathing exercises followed by an enema, while the control group received a standard enema procedure. Significant time, group, and time × group interactions were found for anxiety (d = 1.84), fear (d = 1,36), and pain (d = 1.23) (p < 0.001). The intervention group showed greater reductions in anxiety, fear, and pain compared to the control group (p < 0.001). Within-group analyses showed significant reductions in anxiety (d = 0,83), fear (d = 0,69), and pain (d = 0,43) scores in the intervention group (p < 0.001), while they increased in the control group. Breathing exercises are effective in reducing children's anxiety, fear, and pain levels associated with enemas. Breathing exercises can be recommended as an effective, non-pharmacological nursing intervention for children. Clinical Trials number: NCT05508022.

PMID 42929448
阅读全文 →
PubMedJournal of pediatric surgery2026-10-23

Are Contrast Studies Reliable for Ruling Out Post-Necrotizing Enterocolitis Strictures? A Systematic Review and Meta-Analysis.

Ricci Ester E, Magrini Elisa E, Vincenti Mohamed M, Berardino Melissa M et al.

Intestinal strictures are one of the common late complications of necrotizing enterocolitis (NEC). Contrast studies are among the routinely used imaging modalities for screening post-NEC strictures. This systematic review with meta-analysis aimed to determine the diagnostic accuracy of contrast studies in diagnosing post-NEC strictures. A literature search was conducted across four electronic databases - Scopus, PubMed, ScienceDirect, and Cochrane Library - for all relevant publications published through March 2026. Contingency table data were extracted from all the studies that met the inclusion criteria. The statistical software R version 4.5.3 was used to perform the statistical analysis. The literature search retrieved 582 references, among which 5 were included in the review. All the studies analyzed the diagnostic accuracy of contrast studies (contrast enema (CE) or distal loopogram) in the diagnosis of post-NEC strictures. CE has high diagnostic accuracy for post-NEC stricture, with sensitivities and specificities of 93.30% and 93.57%, respectively. The false-negative rate for CE was 6.70%. There were minimal adverse events during contrast studies, with only one case of iatrogenic perforation. Contrast studies demonstrate high diagnostic accuracy; however, they may miss a clinically relevant proportion of post-NEC strictures and do not consistently influence surgical decision-making. Therefore, contrast studies may not be relied upon as a standalone tool to safely exclude disease, and their routine use must be carefully reconsidered.

PMID 42918490
阅读全文 →
PubMedFrontiers in pediatrics2026-10-23

Patterns and predictors of surgical management in pediatric chronic idiopathic constipation.

Obidike Prisca C PC, Droke Katlyn A KA, Williams Grant F GF, Wainstein Cecily A CA et al.

Chronic idiopathic constipation (CIC) is a common childhood gastrointestinal disorder that substantially affects quality of life and healthcare utilization. Most children are managed successfully with dietary modification, behavioral interventions, and medical therapies. However, many patients experience severe or refractory symptoms that necessitate surgical intervention. We sought to identify patient factors associated with progression to surgical intervention. A retrospective multi-institutional cohort study was performed of children (<18 years of age) who presented to a pediatric surgeon for chief complaint of CIC between 2017 and 2022. The primary outcome was major surgical intervention for the management of CIC. Patient characteristics, including demographic characteristics and clinical variables, were queried, and multivariable logistic regression was used to assess the association between patient factors and surgical intervention. A total of 188 patients were included. Forty patients (21.3%) had a major operation for CIC, including antegrade continence enema (ACE) procedures, intestinal resection, and intestinal diversion. Patients who underwent surgery were older at the time of first visit (mean 9.12 vs. 4.64 years; p < 0.001). In multivariable logistic regression, older age at first pediatric surgery visit was independently associated with surgical intervention. Each additional year of age was associated with approximately 30% higher adjusted odds of surgical intervention (adjusted OR 1.29, 95% CI 1.14-1.48; p < 0.001). Sex, race, ethnicity, insurance type, and neurodiversity were not significantly associated with surgery. Approximately one in five patients referred to a pediatric surgeon for refractory constipation undergo surgical intervention to treat constipation. Older age at presentation was associated with surgical treatment.

PMID 42909081
阅读全文 →
PubMedACS nano2026-10-23

In Situ-Forming Bioresponsive Liposome-Anchored Hydrogel Restores Redox-Immune Homeostasis in Mucosal Macrophages for Radiation-Induced Rectal Injury Repair.

Wen Hong H, Tao Wei W, Fu Yuanyuan Y, Li Menghuan M et al.

Radiation-induced rectal injury (RRI) is a prevalent complication of pelvic radiotherapy that severely affects the life quality of patients, but its effective treatment remains a major challenge in the clinic. Herein, we identify that the redox-immune dyshomeostasis of mucosal macrophages as a major pathological driver of RRI-associated acute inflammation and chronic fibrosis and developed an in situ forming reactive oxygen species (ROS)-responsive liposome-anchored hydrogel (Lip@H151@TK-PF127 Gel) for effective RRI repair. For this purpose, liposomes were further grafted with mannose moieties via thioketal (TK) linkers for loading cGAS-STING inhibitor H151, which were further conjugated onto the TK-PF127 Gel. The Lip@H151@TK-PF127 Gel precursors could be facilely administered to the RRI site via enema and undergo temperature transition to achieve in situ gelation, which would be subsequently activated by local ROS to trigger Lip-TK-Man@H151 release. Lip-TK-Man@H151 could be selectively taken up by inflammatory mucosal macrophage and skew them toward the anti-inflammatory and repair-associated macrophage state through restoring redox-immune homeostasis via cooperative TK-enabled ROS scavenging and cGAS-STING inhibition, hallmarked by upregulated IL-10 expression. Owing to these merits, the Lip@H151@TK-PF127 Gel treatment effectively ameliorated the acute epithelial damage post irradiation while abrogating the risk of intestinal fibrosis in vivo. These findings corroborate Lip@H151@TK-PF127 Gel as a promising strategy for RRI treatment in the clinic.

PMID 42917223
阅读全文 →
PubMedMiddle East journal of digestive diseases2026-10-22

Anti-Tumor Necrosis Factor-Alpha Associated Kaposi Sarcoma in a Patient with Ulcerative Colitis: A Case Report and Literature Review.

Fatemi Reza R, Mahabadi Zeinab Z, Fatemi Seyed Aram SA, Alizadeh Sania S et al.

Kaposi sarcoma (KS) is a rare vascular malignancy associated with human herpesvirus-8 (HHV-8). Tumor necrosis factor-alpha inhibitors (anti-TNF-α agents) are widely used in inflammatory bowel diseases such as ulcerative colitis (UC). While these biologics are effective, they carry a risk of opportunistic infections and, rarely, malignancies. We report a rare case of KS developing in a patient with UC following infliximab treatment. A 67-year-old man with a 3-year history of moderate to severe UC, maintained on azathioprine and mesalazine, initiated induction therapy with infliximab (four 100 mg vials per dose). One week after the first infusion, he developed lower limb edema. Four months later, he presented with multiple violaceous cutaneous plaques. A skin biopsy confirmed KS, and HHV-8 serology was positive. Infliximab was immediately discontinued. The patient subsequently received systemic chemotherapy (liposomal doxorubicin) with complete resolution of the cutaneous lesions. This case highlights KS as a severe, albeit rare, adverse event of anti-TNF-α therapy, emphasizing the need for vigilance, prompt diagnosis, and intervention.

PMID 42903387
阅读全文 →
PubMedBMC pediatrics2026-10-22

Very early onset inflammatory bowel disease in Jordan: a single-center case series of clinical, genetic, and therapeutic features.

Altamimi Eyad E, Almomani Hala H, Alsmadi Ayah A, Issi Nicole N et al.

Very early onset inflammatory bowel disease (VEOIBD), defined as onset before six years of age, is increasingly recognized as a distinct entity often linked to monogenic etiologies. Data from the Middle East remain limited. We conducted a retrospective case series of ten pediatric patients diagnosed with VEOIBD at King Abdullah University Hospital, Jordan, between July 2017 and July 2024. Clinical, endoscopic, histopathologic, genetic, treatment, and outcome data were extracted and analyzed descriptively. The cohort comprised ten patients (six males, four females). Median age at symptom onset was 12 months (range 3-60), with median diagnosis at 34 months (range 10-72). Diarrhea (100%), failure to thrive (60%), and recurrent infections (40%) were predominant presenting features. Endoscopy revealed mucosal ulceration in seven patients (70%), with non-caseating granulomas in three (30%) and focal active colitis in three (30%). Genetic testing (n = 8) identified pathogenic or likely pathogenic variants in six patients and variants of uncertain significance (VUS) in two; the genes implicated were MEFV (n = 3), CYBB (n = 2; both VUS), G6PC3, GUCY2C, NPC1, NOD2, RIPK1, and LRBA. Three patients carried variants in two genes. In one pair - a homozygous pathogenic NPC1 frameshift variant with a heterozygous NOD2 VUS - a composite digenic mechanism has been proposed as a candidate contributor to the unusually severe VEOIBD phenotype [21]. Therapies included infliximab (n = 4), mesalazine, azathioprine, budesonide, intravenous immunoglobulin, elemental diet, and colchicine. Three patients were referred for hematopoietic stem cell transplantation (HSCT); one died of infection-related multi-organ failure. The patient with a homozygous LRBA VUS lacked access to targeted therapy with abatacept or sirolimus. VEOIBD in Jordan is characterized by early presentation, genetic heterogeneity including co-occurring variants of uncertain significance, and poor response to conventional therapy. Limited access to targeted agents and HSCT significantly impacts outcomes. Early genomic testing, multidisciplinary management, and improved therapeutic access are essential for better prognosis.

PMID 42907806
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多mesalazine